Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insight Molecular Diagnostics Inc (IMDX)

Insight Molecular Diagnostics Inc (IMDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 147,620
  • Shares Outstanding, K 28,664
  • Annual Sales, $ 1,880 K
  • Annual Income, $ -60,660 K
  • EBIT $ -19 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.18
  • Price/Sales 75.28
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 800.13% (+35.56%)
  • Historical Volatility 85.67%
  • IV Percentile 44%
  • IV Rank 49.69%
  • IV High 1,085.04% on 12/05/25
  • IV Low 518.79% on 11/12/25
  • Expected Move (DTE 8) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 23
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 166
  • Open Int (30-Day) 126
  • Expected Range 5.09 to 5.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.48
  • Growth Rate Est. (year over year) +208,025.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.91 +3.67%
on 12/09/25
8.51 -40.19%
on 11/12/25
-1.71 (-25.15%)
since 11/10/25
3-Month
2.90 +75.52%
on 09/11/25
8.51 -40.19%
on 11/12/25
+2.09 (+69.67%)
since 09/10/25
52-Week
1.92 +164.83%
on 01/22/25
8.51 -40.19%
on 11/12/25
+2.59 (+103.60%)
since 12/10/24

Most Recent Stories

More News
This Biotech Stock Is Up 158% in a Year. What’s Driving It Higher?

Insight Molecular Diagnostics (IMDX) is a precision diagnostics company with disruptive transplant technology and strong recent price momentum. IMDX has surged 158% over the past year and is trading at...

IMDX : 5.09 (-1.17%)
Insight Molecular Diagnostics: Q3 Earnings Snapshot

Insight Molecular Diagnostics: Q3 Earnings Snapshot

IMDX : 5.09 (-1.17%)
IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

On track to submit GraftAssureDx™ for FDA review by year-end On track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025 GraftAssure assay’s...

IMDX : 5.09 (-1.17%)
iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market...

IMDX : 5.09 (-1.17%)
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future products Brings 25 years of experience driving new product adoption across geographies in transplantation,...

IMDX : 5.09 (-1.17%)
Insight Molecular Diagnostics (IMDX) Gets a Buy from Lake Street

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Insight Molecular Diagnostics, with a price target of $8.00. The company’s shares closed last Friday at $3.35.Elevate...

IMDX : 5.09 (-1.17%)
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring

American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancers GraftAssure used to...

IMDX : 5.09 (-1.17%)
Insight Molecular Diagnostics Extends Executive Employment Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Insight Molecular...

IMDX : 5.09 (-1.17%)
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

IMDX to host symposium on Wednesday, September 24 th to discuss GraftAssureIQâ„¢ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting Presenting...

IMDX : 5.09 (-1.17%)
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partners New hospital-based data seeks to further differentiate pending kitted assay that measures biomarker...

IMDX : 5.09 (-1.17%)

Business Summary

Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 5.36
2nd Resistance Point 5.30
1st Resistance Point 5.20
Last Price 5.09
1st Support Level 5.04
2nd Support Level 4.98
3rd Support Level 4.88

See More

52-Week High 8.51
Fibonacci 61.8% 5.99
Fibonacci 50% 5.22
Last Price 5.09
Fibonacci 38.2% 4.44
52-Week Low 1.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar